Skip to main content

Extrapyramidal Reaction News

Related terms: Extrapyramidal Symptoms

Study Reveals No Link Between HDL Cholesterol and Movement Disorders

FRIDAY, Sept. 20, 2024 – There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient's risk for developing movement disorders while taking an antipsychotic, a...

FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions

BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous sy...

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine)...

FDA Medwatch Alert: Benztropine Mesylate Injection (Nexus Pharmaceuticals): Recall - Visible Particulate Matter

ISSUE: Nexus Pharmaceuticals Inc. is recalling two lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the presence of visible particulate matter in the...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Tardive Dyskinesia

Related drug support groups

Benadryl, diphenhydramine, amantadine